Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 Under 1%, & High TMB? New Data from CheckMate 227 (BMIC-040)
Jun 22, 2018•9 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in patients with low PD-L1 and high tumor mutation burden (TMB).
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast